Enhancing Antitumor Immunity of FasL-Transfected Lewis Lung Carcinoma Is Used by Dendritic Cell-Based Vaccine

• Main Authors: Yi-Lin Tsai, 蔡一麟
• Other Authors: Shye-Jye Tang
• Format: Others
• Language: zh-TW
• Published: 2004
• Online Access: http://ndltd.ncl.edu.tw/handle/38866978641976551875

碩士 === 國立臺灣海洋大學 === 生物科技研究所 === 92 === Abstract The malignant tumor is a serious disease in human today. Conventional treatments for it include surgery, chemotherapy, and radiation therapy used alone or in combination. Despite the increasingly intense application and continuous modification of these approaches，the overall cure rate for malignant tumor remains poor. The treatments mentioned above could not be effective and specific to eradicate tumors in patients. Thus , due to explore new treatment options is paramount, the concepts of gene therapy and immunotherapy of cancer come to existence. Recent clinical studies have shown that immunotherapeutics with DC-based cancer vaccines have the potential to improve patient outcome for a wide range tumor types. In addition, forced expression of FasL in tumors can induce the effect of gene therapy. In present study, we use DC-based vaccine to induce protective immunity to resist Lewis lung carcinoma combined with FasL-LLC. The results demonstrate that DC-based vaccine implanted in mice alone could produce antitumor immune responses against lung carcinoma to delay tumor growth and survival in mice. However, we don’t observe the significant effect in combined studies with FasL-LLC, but it could still be as a prototype to provide a novel strategy in combined tumor therapy.